Hepion Pharmaceuticals Email Format

Biotechnology ResearchNew Jersey, United States2-10 Employees

Hepion Pharmaceuticals is a small biotechnology company based in Morristown, New Jersey, focusing on liquid biopsy diagnostics for cancer, with the aim of integrating diagnostics and therapeutics in a closed-loop theranostics model. It holds global commercialization rights to two genomic-based tests for liver cancer detection and surveillance: a methylated SEPT9 (mSEPT9) assay and a circulating tumor RNA (ctRNA) platform. The ctRNA asset is licensed from Cirna Diagnostics, a spinout from the Baruch S. Blumberg Institute, while the mSEPT9 test is described as a validated biomarker with clinical evidence. The tests target hepatocellular carcinoma in high-risk cirrhotic patients, with potential applications across other solid tumors.

Hepion operates in the biotechnology research sector, seeking to address gaps in early liver cancer detection where current screening misses a substantial portion of cases. The company emphasizes its IP position and flexibility in business models to partner and create value in oncology diagnostics. In March 2026, Hepion launched a ctRNA biomarker assay to enhance early detection of HCC in high-risk patients, complementing its methylated DNA test.

Get verified Hepion Pharmaceuticals emails free

Company overview Employee directory